Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.19.1
Commitments and Contingencies (Details Textual)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2019
USD ($)
Mar. 15, 2019
USD ($)
$ / shares
Mar. 11, 2019
Oct. 09, 2018
USD ($)
Apr. 01, 2018
USD ($)
Dec. 14, 2017
Mar. 24, 2019
USD ($)
shares
Dec. 19, 2018
USD ($)
Nov. 21, 2018
USD ($)
Nov. 16, 2018
Oct. 31, 2018
Jul. 31, 2018
Feb. 17, 2015
Jan. 31, 2011
Mar. 31, 2019
USD ($)
$ / shares
Mar. 31, 2019
EUR (€)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
EUR (€)
Mar. 31, 2019
€ / shares
Commitments and Contingencies (Textual)                                        
Minimum royalties accrued                             $ 10,000     $ 40,000    
Cost of agreement                             71,250          
Performance bonus plan, description                         Under the PBP, 5.25% of the first $14.7 million of a strategic transaction (one or more transactions that provide funds to the Company and/or its members that enable the commencement of the clinical development of AD04) will be set aside for Company's personnel with 1.25% of funds to be awarded to the Chairman of the Board and the remainder to be awarded at the CEO's discretion, with no more than 3.15% payout to the CEO of the Company. The maximum bonus amount to be paid out of the PBP was $771,750. The Company had the right to pay up to 65% of the amounts due under the PBP with equity of the Company, valued at a future investors round equity price, with the balance paid in cash in order to potentially pay taxes that may be due by the recipients due to the award under the PBP.              
Associated charge to operations                                   1,500,000    
Employment agreements terms, description     The employment agreement of the CEO and COO/CFO were amended, raising their salaries to $400,000 per year and $150,000 per year (at a 50% time commitment), respectively.                 The CEO and COO/CFO executed their respective employment agreements for terms ranging from three to five years, salaries ranging from $325,000 per year to $143,000 per year (at a 50% time commitment), with customary terms of severance.                
Grant incentive plan, description         The Company will make a yearly payment to the Plan Participant, based on the grant funding received by the Company in the preceding year from grants originated by the Plan Participants, in an amount equal to 10% of the first $1 million of grant funding received and 5% of grant funding received in the preceding year above $1 million. Amounts to be paid to the Plan Participants will be paid to each as follows: 50% in cash and 50% in stock no later than March 31, each year.                              
Prepaid research and development                             379,670     $ 505,960    
Prepaid research and development expenses                             (126,290)        
Mr. Stilley [Member]                                        
Commitments and Contingencies (Textual)                                        
Shares of common stock         $ 197,673                              
Dr. Johnson [Member]                                        
Commitments and Contingencies (Textual)                                        
Shares of common stock         50,000                              
Mr. Truluck [Member]                                        
Commitments and Contingencies (Textual)                                        
Shares of common stock         $ 44,636                              
Master services agreement [Member]                                        
Commitments and Contingencies (Textual)                                        
Description of master services agreement                     The MSA has a term of five years, automatically renewed for two year periods, unless either party gives written notice of a decision not to renew the agreement three months prior to automatic renewal. The agreement can be terminated by the Company if, in the Company's reasonable opinion, clinical or non-clinical data support termination of the clinical research for safety reasons.                  
Service agreement 1 [Member]                                        
Commitments and Contingencies (Textual)                                        
Description of master services agreement                   The Company and Crown entered into Service Agreement 1 under the MSA for a 24 week, multi-centered, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical study of the Company's lead compound, AD04. The MSA or a service agreement under it may be terminated by the Company, without penalty, on fourteen days written notice.                    
Estimated cost                             2,400,000          
Service agreement 1 [Member] | Euro [Member]                                        
Commitments and Contingencies (Textual)                                        
Estimated cost | €                               € 2,172,000        
Service Order [Member]                                        
Commitments and Contingencies (Textual)                                        
Fee for completion of trial under service                             $ 3,300,000          
Euro/US dollar exchange rate | $ / shares                             $ 1.1221          
Prepayment under the agreement cost                 $ 505,960                      
Service Order [Member] | Euro [Member]                                        
Commitments and Contingencies (Textual)                                        
Fee for completion of trial under service | €                                     € 2,952,355  
Euro/US dollar exchange rate | € / shares                                       € 1.1221
Vendor Agreement [Member]                                        
Commitments and Contingencies (Textual)                                        
Vendor Agreements, description                             The Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services, with terms ranging between 12 and 30 months. These agreements, in aggregate, commit the Company to approximately $1.1 million in future payments and future issuance of 87,500 shares of common stock over their respective terms. The Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services, with terms ranging between 12 and 30 months. These agreements, in aggregate, commit the Company to approximately $1.1 million in future payments and future issuance of 87,500 shares of common stock over their respective terms.        
Licensing & Venture Group [Member]                                        
Commitments and Contingencies (Textual)                                        
License agreement description                           The Company is obligated to pay UVA LVG yearly license fees and milestone payments, as well as a royalty based on net sales of products covered by the patent-related rights. More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense itself. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.            
License agreement notice period, description                           The license agreement may be terminated by UVA LVG upon sixty (60) days written notice if the Company breaches its obligations thereunder, including failing to make any milestone, the most immediate being initiating Phase 3 clinical trials by December 31, 2019, making required payments or the failure to exercise diligence to bring licensed products to market.            
License agreement amendment changed dates, description           This amendment changed the dates by which the Company, using commercially reasonable efforts, was to achieve the goals of submitting a New Drug Application to the FDA for a licensed product to December 31, 2024 (from December 31, 2023) and commencing commercialization of an FDA approved product by December 31, 2025 (from December 31, 2024).                            
Lyons Capital, LLC [Member]                                        
Commitments and Contingencies (Textual)                                        
Shares of common stock   $ 18,750                                    
Shares issued price per share | $ / shares   $ 3.46                                    
Compensation rate of consulting agreement   $ 64,875                                    
Consulting Agreement [Member] | Dr. Bankole A. Johnson [Member]                                        
Commitments and Contingencies (Textual)                                        
Consultant fees                             $ 267,191          
Annual salary             $ 375,000                          
Bonus             $ 250,000                          
Option to purchase | shares             250,000                          
Consulting Agreement [Member] | Bespoke Growth Partners, Inc. [Member]                                        
Commitments and Contingencies (Textual)                                        
Lease agreement fee $ 50,000                                      
Office Service Agreement [Member]                                        
Commitments and Contingencies (Textual)                                        
Monthly payments of lease               $ 1,150                        
Rent expense                             $ 3,450          
License and Membership Agreement [Member]                                        
Commitments and Contingencies (Textual)                                        
License agreement description       The Company agreed to pay a monthly fee of $1,152 for membership and use of these facilities, committing to do so for a term of one year.                                
Rent expense       $ 3,455